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Purpose/Objective: The scheme of standard radiotherapy for 
breast cancer treatment involves a high total dose in 25 
fractions. However, a decrease in the total dose, together 
with an increase in the dose per fraction (hypofractionation) 
is discussed to be at least as effective as standard treatment. 
The objective of our study is to analyze the results in local 
control, acute and late toxicity and cosmetic outcome in 
patients treated with hypofractionated radiation therapy 
after conservative surgery for breast cancer in our center. 
Materials and Methods: A retrospective analysis of all women 
diagnosed with breast cancer (Stage 0-III) and treated with 
breast-conserving surgery followed by hypofractionated 
scheme from 2006 to 2011. Total dose on mammary gland: 
42.4 Gy to 2.65 Gy / fraction, for a total of 16 sessions with 
concomitant boost to 7.7 Gy (0.48 Gy / fraction). We 
included patients treated with chemotherapy, hormonal 
therapy and trastuzumab. Acute and late toxicities were 
scored according to the Common Terminology Criteria for 
adverse Events version 4.0 and cosmetic outcome were 
assessed during follow-up every three months up to 2 years 
and every six months up to 5 years after radiotherapy.  
Results: We have treated 143 women with hypofractionated 
scheme. After a median follow up of 36 months, the local 
recurrence rate was 1.4%, only 3.5% experienced nodal 
relapse, one patient developed a contralateral breast cancer 
and 6.3% had distant metastases as first event. There was no 
acute toxicity in 28.4% of cases, being the most frequent 
grade 1 radiodermatitis (61.1%). Regarding late toxicity, this 
was not observed in 65.6%, being grade 1 fibrosis in the 
treated area the most common. The cosmetic outcome was 
good or excellent in 90% of patients treated. At the end of 
the study, 83.8% remained alive without disease, 7% alive 
with disease, 4.9% exitus due to tumor and 4.2% were died 
due to other causes. 
Conclusions: The hipofractionated scheme after conservative 
surgery in breast cancer provides a good control of the 
disease without causing excessive toxicity and providing good 
cosmetic outcomes. Similar results to standard treatment can 
be obtained with a significant reduction in overall treatment 
time. 
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Purpose/Objective: Early breast cancer treated with breast 
conservative therapy (BCT), usually has a good prognosis. 
Recommended target field of RT field is whole breast. 
However, added to the results from MA.20 about regional 
nodal irradiation (RNI) to patients with pN1 status, EORTC 
22922/10925 reported the benefit of RNI for overall survival 
including internal mammary and medial supraclavicular 
lymph node chain especially in tumors situated in medial 
(=inner/central) site without axillary lymph node metastasis. 
Based on our long term date specifically focused on tumor 
site, we assessed the possible utilization of RNI for 
application guideline of breast cancer in Japan. 
Materials and Methods: A total number of patients who were 
treated with BCT are 1200 in our institution. Patients with 
simultaneous bilateral breast cancer and non-invasive breast 
cancer were excluded. Cases with RNI were also excluded. 
1079 cases out of 1200 treated with BCT until December 2012 
were analyzed. 
Median age at diagnosis is 53 years (range: 25-85). Major 
histological type is invasive ductal cancer (93.4%). Tumor 
sizes of origin was in T1; 65.0%, T2; 32.6%, and T3; 1.1%. 
Positive lymph node metastasis was seen in 24.7%. 37.6% of 
patients received chemotherapy, and 73.3% underwent 
hormone therapy. All patients were treated with 
postoperative whole breast RT, in which 37.8% received boost 
RT of 10-14Gy. 
Results: Median follow up period was 120 months (range: 4-
300). A number of tumors located in inner site was 393 
(36.8%), and a number of tumors in outer site was 676 
(63.2%). According to EORTC trial, centrally situated cases 
were regarded as inner cases at the analysis. Ten year overall 
survival rate was favorable (90.1% at inner site and 92.7% at 
outer site (p=0.189)), local recurrence free survival (LRFS) at 
inner/outer site were 90.1%/93.7% (p=0.79), distant 
metastasis free survival (DMFS) were 88.4%/90.1% (p=0.594), 
and disease free survival (DFS) were 72.9%/79.4% (p=0.03) 
respectively. Only DFS was significantly better in outer 
group. 
In cases with positive nodes, LRFS, DMFS, and DFS were not 
significantly different between inner and outer sites. Notably 
in cases with negative nodes, LRFS/DFS/OS of inner situated 
cases were statistically significantly worse. 
Conclusions: In current clinical practice, the whole breast RT 
is recommended to patients with inner situated tumors, 
however, especially in the patients with negative nodes, RNI 
should be considered as a state of the art strategy. 
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Purpose/Objective: Neoadjuvant systemic therapy (NAST) in 
breast cancer potentially down-stages disease, thereby 
posing challenges to the standard indications for nodal 
irradiation. We assessed the pattern of NAST utilization in our 
province and its effect on the recommendation for nodal 
radiotherapy (RT). 
Materials and Methods: Of the 11,628 patients with stages I 
to III breast cancer from 2007-2012, 603 patients (5.2%) were 
treated with NAST. Data from our provincial database were 
obtained to determine relationships between NAST use and 
nodal irradiation. 
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Results: The median age of patients who received NAST was 
52 years (range 25 - 91 years). 90% received chemotherapy, 
64% were assessed with clinical and/or imaging studies, 34% 
had FNAs, and 2% had preoperative sentinel lymph node 
biopsies. All patients who had sentinel lymph node biopsies 
had clinically negative nodes. 91% of patients had nodal 
irradiation after NAST. On logistic regression analysis, NAST 
utilization was lower in 3 out of 5 centres compared with the 
largest centre (p < 0.05). Increasing tumour and nodal stage 
were the main predictors for NAST use (p-value <0.001). 
There was a decreased use of NAST with time compared to 
2007, but this was not statistically significant (p-value 0.34). 
Conclusions: Contrary to our initial hypothesis, there has not 
been a significant increase in NAST over time. Nodal 
irradiation is used in the majority of patients who received 
NAST. Clinical nodal status did not predict for subsequent 
nodal irradiation. 
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Purpose/Objective: Comparison of acute radiotherapy side 
effects and dosimetric parameters between breast cancer 
patients receiving breast conserving radiotherapy using 
simultaneous integrated boost (SIB) and sequential electron 
boost technique. 
Materials and Methods: 58 breast cancer patients who 
underwent Breast Conserving surgery and received adjuvant 
radiotherapy with either simultaneous integrated photon 
boost (SIB) or sequential electron boost technique were 
retrospectively selected. In the SIB group, 30 consecutive 
patients were treated with a total dose of 45.57Gy to the 
whole breast and 56.07 Gy to the tumour bed in 21 
concomitant fractions from January to May 2013. In the 
electron group, 28 consecutive patients were treated with a 
total dose of 50Gy in 25 fractions to the whole breast 
followed by 16Gy in 8 fractions sequential electron boost to 
the tumour bed from January to April 2012. Skin toxicities 
were prospectively assessed during on-treatment follow up 
using RTOG skin toxicity grading. Boost volume and dose 
parameters to organ at risk were compared between the 2 
groups. 
Results: 6.67% and 28.6% of patients developed Grade2 or 
above skin toxicity by RTOG skin toxicity grading for SIB and 
electron group respectively (p=0.038). The mean boost 
volume was 64.2cm3 and 202.9cm 3for SIB and electron group 
respectively (p<0.001). There were no statistically significant 
difference between the mean lung dose :5.52Gy and 5.09Gy 
for electron and SIB group respectively (p=0.301) ; V20 for 
lung:9.16% and 8.14% for electron and SIB respectively 
(p=0.266) ; V10 for heart: 1.74% and 3.16% for electron and 
SIB group respectively(p=0.107). 
Conclusions: Simultaneous integrated boost technique for 
adjuvant radiotherapy following breast conserving surgery 
has the benefit of a favorable acute toxicity profile, reduced 
number of treatment fractions and comparable dose to organ 
at risk with conventional sequential electron boost 
technique. 
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Purpose/Objective: The dose-volume effect of radiotherapy 
on breast tissue is not well known existing conflicting results 
in the literature. Some studies suggest that there are higher 
rates of fibrosis in patients treated with large boosts and 
other studies downplay the impact of the implant volume, 
suggesting that what really determines the increase of 
fibrosis is the total dose of the boost and surgical factors like 
a poorly planned excision and a large volume of breast 
removed. Most of the studies that address these issues are 
old and usually boost large volumes of the breast, even more 
than 100cc. Current modalities of conservative treatment 
with tighter surgical margins and imaging techniques that 
allow us to localize the tumor bed more accurately have 
meant that the volumes of brachytherapy implants have 
decreased dramatically and this may have influence in 
toxicity. The purpose of the study was to evaluate if there is 
any relationship between the implant volumes with long term 
toxicity. 
Materials and Methods: We evaluated all the patients who 
received a High Dose Rate (HDR) boost in our department 
after irradiating the whole breast following conservative 
surgery. In all patients an MRI of the breast was performed 
before surgery to determine the most appropriate surgical 
modality. We used this MRI and the planning CT (surgical 
clips, seroma) as a reference to perform the brachytherapy 
implant and minimize the boost volume. 
Results: We treated 220 boosts with a mean following time of 
14months (6-24mo). 87.7% breasts were previously treated 
under the hypofractionated scheme of the START B trial 
(40,05Gy/15fractions) and 12.3% were conventional 
treatments (50Gy/25 fractions). 50.9% were left breast 
cancers and the tumor bed was localized in upper external 
quadrant in 30%. 98.2% received 8Gy and 1.8% 10Gy. The 
mean implant volume of the isodose of the 90% of the 
prescribed dose was 8.19cc, 120%: 1.25cc, 150%: 0.16cc and 
200%: 0.04cc. Prescription dose was based on the modified 
Paris dosimetry treatment. Chronically, fibrosis was absent or 
mild in 83.2%%. The remaining patients suffered from 
moderate fibrosis (grade 2). Only one case of grade 3 was 
reported. 7.3% of patients reported visible and palpable 
edema in the skin over the implant. We did not find a 
statistically significant relation between the implant volumes 
and the grade of long term fibrosis or edema. 
Conclusions: HDR-BRT boost after whole breast irradiation is 
a safe and widespread technique to administer a breast boost 
in patients at risk, which is not exempt from suffering long 
term complications. In our retrospective study we couldn´t 
prove the relationship between the implant volume and long 
term toxicity (fibrosis and edema). Prospective studies 
comparing different boost doses and volumes are needed to 
